Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04318249 Not yet recruiting - Insomnia Clinical Trials

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

LC_ART
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This is a randomized, 30-day research study that is exploring the effects of two simplified mindfulness interventions in lung cancer patients aimed to improve their sleep quality and anxiety regarding sleep. The investigators will be enrolling a total of 20 patients who have insomnia symptoms. Patients will use a behavioral intervention to help with their sleep.

NCT ID: NCT04314297 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Start date: April 2020
Phase: Phase 2
Study type: Interventional

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NCT ID: NCT04306926 Not yet recruiting - Clinical trials for Advanced Oligometastatic Non-small Cell Lung Cancer

A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer

Start date: March 2020
Phase: Phase 2
Study type: Interventional

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

NCT ID: NCT04304638 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Start date: March 2020
Phase:
Study type: Observational

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.

NCT ID: NCT04266730 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

PANDA-VAC
Start date: August 22, 2024
Phase: Phase 1
Study type: Interventional

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

NCT ID: NCT04263688 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion

Start date: March 1, 2020
Phase:
Study type: Observational

Multicenter observational study for correlation between tumor mutation burden and immunotherapy efficacy of advanced non-small cell lung cancer with malignant pleural effusion

NCT ID: NCT04239833 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Start date: January 31, 2020
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

NCT ID: NCT04234607 Not yet recruiting - Clinical trials for Extensive Small Cell Lung Cancer

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Start date: January 2020
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer. The primary outcome measures include PFS and OS. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1:1 to the experimental arms and the control arm.

NCT ID: NCT04211896 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of anlotinib in combination with nivilumab as second-line treatment in advanced NSCLC patients. The primary endpoint of the study is progression-free survival (PFS);the secondary endpoints are disease control rate (DCR), objective response rate (ORR), overall survival (OS) and safety.

NCT ID: NCT04203485 Not yet recruiting - Clinical trials for PD-L1 Positive Non-small Cell Lung Cancer

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.